129 related articles for article (PubMed ID: 35835630)
1. Perspectives for licensing vaccines in Mexico.
Padron-Regalado E; Medina-Rivero E
Vaccine; 2022 Aug; 40(34):4979-4985. PubMed ID: 35835630
[TBL] [Abstract][Full Text] [Related]
2. Regulatory Pathway for Licensing Biotherapeutics in Mexico.
López-Morales CA; Tenorio-Calvo A; Cruz-Rodríguez R; Sánchez Y Tepoz J; Belgharbi L; Pérez-Tapia SM; Medina-Rivero E
Front Med (Lausanne); 2018; 5():272. PubMed ID: 30320117
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the Latin America Regulation Landscape and International Reference Health Authorities to Hasten Drug Registration and Clinical Research Applications.
Argotti U; Leyens L; Lisbona C; López P; Alonso-Orgaz S; Nevado A; Cozzi V
Ther Innov Regul Sci; 2023 Nov; 57(6):1287-1297. PubMed ID: 37682461
[TBL] [Abstract][Full Text] [Related]
4. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
Amanpour S
Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
[TBL] [Abstract][Full Text] [Related]
5. Latin American Scientific Production on COVID-19 Vaccines.
Hernández RM; Esteban RFC; Mamani-Benito O; Chaparro JET; Saavedra-López MA; Calle-Ramirez XM; Wong-Fajardo M; Campos-Ugaz O
Ethiop J Health Sci; 2022 Mar; 32(2):235-242. PubMed ID: 35693566
[TBL] [Abstract][Full Text] [Related]
6. Vaccines for a healthy future: 21st DCVMN Annual General Meeting 2020 report.
Pagliusi S; Hayman B; Jarrett S
Vaccine; 2021 Apr; 39(18):2479-2488. PubMed ID: 33838948
[TBL] [Abstract][Full Text] [Related]
7. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
[TBL] [Abstract][Full Text] [Related]
8. Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal.
Drugs R D; 2003; 4(5):312-9. PubMed ID: 12952502
[TBL] [Abstract][Full Text] [Related]
9. COVID-19 vaccines: concerns beyond protective efficacy and safety.
Lai CC; Chen IT; Chao CM; Lee PI; Ko WC; Hsueh PR
Expert Rev Vaccines; 2021 Aug; 20(8):1013-1025. PubMed ID: 34180347
[TBL] [Abstract][Full Text] [Related]
10. Clinical development and approval of COVID-19 vaccines.
Kalinke U; Barouch DH; Rizzi R; Lagkadinou E; Türeci Ö; Pather S; Neels P
Expert Rev Vaccines; 2022 May; 21(5):609-619. PubMed ID: 35157542
[TBL] [Abstract][Full Text] [Related]
11. The effect of framing and communicating COVID-19 vaccine side-effect risks on vaccine intentions for adults in the UK and the USA: A structured summary of a study protocol for a randomized controlled trial.
Sudharsanan N; Favaretti C; Hachaturyan V; Bärnighausen T; Vandormael A
Trials; 2021 Sep; 22(1):592. PubMed ID: 34488843
[TBL] [Abstract][Full Text] [Related]
12. Barriers to COVID-19 vaccination among older adults in Mexico City.
Gaitán-Rossi P; Mendez-Rosenzweig M; García-Alberto E; Vilar-Compte M
Int J Equity Health; 2022 Jun; 21(1):85. PubMed ID: 35717236
[TBL] [Abstract][Full Text] [Related]
13. COVID-19 vaccine trials: The use of active controls and non-inferiority studies.
Fleming TR; Krause PR; Nason M; Longini IM; Henao-Restrepo AM
Clin Trials; 2021 Jun; 18(3):335-342. PubMed ID: 33535811
[TBL] [Abstract][Full Text] [Related]
14. [Technical guidelines for seasonal influenza vaccination in China (2021-2022)].
National Immunization Advisory Committee (NIAC) Technical Working Group (TWG) , Influenza Vaccination TWG
Zhonghua Liu Xing Bing Xue Za Zhi; 2021 Oct; 42(10):1722-1749. PubMed ID: 34814607
[TBL] [Abstract][Full Text] [Related]
15. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
16. Editorial: First Full Regulatory Approval of a COVID-19 Vaccine, the BNT162b2 Pfizer-BioNTech Vaccine, and the Real-World Implications for Public Health Policy.
Parums DV
Med Sci Monit; 2021 Sep; 27():e934625. PubMed ID: 34483336
[TBL] [Abstract][Full Text] [Related]
17. Vaccines and Public Trust: Containing COVID-19 in Cuba.
Gorry C
MEDICC Rev; 2022 Jan; 24(1):9-13. PubMed ID: 35157633
[TBL] [Abstract][Full Text] [Related]
18. [Analysis of the evidence on the efficacy and safety of CYD-TDV dengue vaccine and its potential licensing and implementation through Mexico's Universal Vaccination Program].
Hernández-Ávila M; Lazcano-Ponce E; Hernández-Ávila JE; Alpuche-Aranda CM; Rodríguez-López MH; García-García L; Madrid-Marina V; López Gatell-Ramírez H; Lanz-Mendoza H; Martínez-Barnetche J; Díaz-Ortega JL; Ángeles-Llerenas A; Barrientos-Gutiérrez T; Bautista-Arredondo S; Santos-Preciado JI
Salud Publica Mex; 2016; 58(1):71-83. PubMed ID: 26879510
[TBL] [Abstract][Full Text] [Related]
19. Cuba's National Regulatory Authority & COVID-19: Olga Lidia Jacobo-Casanueva MS Director, Center for State Control of Medicines and Medical Devices (CECMED).
Aguilar-Guerra TL; Fajardo-Díaz EM; Gorry C
MEDICC Rev; 2021; 23(3-4):9-14. PubMed ID: 34516531
[TBL] [Abstract][Full Text] [Related]
20. Medicinal Product Development and Regulatory Agilities Implemented During the Early Phases of the COVID-19 Pandemic: Experiences and Implications for the Future-An Industry View.
Geraci G; Bernat J; Rodier C; Acha V; Acquah J; Beakes-Read G
Ther Innov Regul Sci; 2023 Sep; 57(5):940-951. PubMed ID: 37266868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
